Why the study?
Does apixaban improve efficacy and safety for stroke prevention in patients with atrial fibrillation and comorbidities?
Does apixaban improve efficacy and safety for stroke prevention in patients with atrial fibrillation and comorbidities?
Answers are grounded in this paper and cite their sources.
Apixaban is highlighted as an effective and safe anticoagulant for stroke prevention in atrial fibrillation patients with multiple comorbidities.
In the article questions of prevention of stroke, including repeated ones, are considered. The choice of anticoagulant therapy is discussed in patients with atrial fibrillation and a number of concomitant diseases - coronary artery disease, diabetes mellitus, chronic kidney disease, chronic heart failure. The data of subanalyses of a randomized clinical trial of ARISTOTLE are presented, indicating a high profile of efficacy and safety of the new oral anticoagulant apixaban in these categories of patients.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: